Neuroprotection with or without erythropoiesis; sometimes less is more
- PMID: 17533424
- PMCID: PMC2189815
- DOI: 10.1038/sj.bjp.0707287
Neuroprotection with or without erythropoiesis; sometimes less is more
Abstract
Erythropoietin (EPO) is a pleiotropic cytokine with a therapeutic potential that goes well beyond the treatment of anaemia. The study by Wang et al (2007b) examined the protective effects of EPO in a rat model of embolic stroke. The efficacy and haematological side effects of EPO were compared to those of a carbamylated EPO variant (CEPO). Treatment with EPO dose-dependently reduced infarct volume and improved long-term functional outcome. However, an increase in hematocrit was seen even for doses of EPO that did not offer neuroprotection. These data do not suggest the existence of a therapeutic window between effect and side effect for treatment with EPO. Treatment with CEPO was without haematological side effects.
Comment on
-
Post-ischemic treatment with erythropoietin or carbamylated erythropoietin reduces infarction and improves neurological outcome in a rat model of focal cerebral ischemia.Br J Pharmacol. 2007 Aug;151(8):1377-84. doi: 10.1038/sj.bjp.0707285. Epub 2007 Jul 2. Br J Pharmacol. 2007. PMID: 17603558 Free PMC article.
References
-
- Coull AJ, Rothwell PM. Underestimation of the early risk of recurrent stroke: evidence of the need for a standard definition. Stroke. 2004;35:1925–1929. - PubMed
-
- Leist M, Ghezzi P, Grasso G, Bianchi R, Villa P, Fratelli M, et al. Derivatives of erythropoietin that are tissue protective but not erythropoietic. Science. 2004;305:239–242. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
